Substitute for form 1449A/PTO	Complete if Known			
	Application Number			
INFORMATION DISCLOSURE	Filing Date			
STATEMENT BY APPLICANT	First Named Inventor	Thomas N.	THOMAS	
OTATEMEN, I DI ATTE DANT	Art Unit			
(Use as many sheets as necessary)	Examiner Name			
Sheet	Attorney Docket Number			

			U. S. PATENT D	OCUMENTS	<u> </u>
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		us-6, 432, 991	08-13-2002	Thomas, TN	Pages 1−1.3
		us-6,635,667	10-21-2003	Thomas, TN	Pages 1-13
		US-6,482,846	11-19-2002	Garvey DS, et al	pages 1-33
		US-6,593,347	07-15-2003	Bandazage UK, et al.	pages 1-15
		US-6,544,556	04-08-2003	Chen CM, et al	pages 1-14
	ļ	us-6, 613, 784	09-02-2003	Bonedini F, et al	pages 1-10
		us-6,649,629	11-18-2003	Bandadage UK, et of	pages 1-40
		บร-	-		
		US-	,		
		US-	-		
ay . If the extension of the addition of the tension of the		US-			
a referen e vedella sensid e a se de viralden vir		US-		and a response of the sector o	
*		US-			
	1	US-		h (in the man is not a three districtions and colored section of the	
	1	US-		n de francisco de de destrucción de la martina con de contra de contra revierto de delse de delse de del de de	
	1	US-			
	1	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁸ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	1.0

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006, OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known
	Application Number	
INFORMATION DISCLOSURE	Filing Date	Thomas N. Thomas
STATEMENT BY APPLICANT	First Named Inventor	Thomas N. Thomas
••	Art Unit	
(Use as many sheets as necessary)	Examiner Name	
Sheet of	Attorney Docket Number	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, Journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ2
	1	Lauer MS. Aspirin for primary prevention of coronary events. N Engl J Med, 346: 1468-1474, 2002.	/
	2	Fennerty BM. NSAID-related gastrointestinal injury. Postgraduate Medicine, 110: 87-94, 2001.	
	3	Yeomans ND. Approaches to healing and prophylaxis of nonsteroidal antiinflammatory Drug-associated ulcers. Am. J. Medicine. 110/1A: 24S - 28S, 2001	/
	4	GlavinGB, et al. L-deprenyl attennuates stress ulcer formation in rats. Neurosci. Letters. 70: 379-381 (1986).	/
	5	ThyagaRajan S. Anti-tumor effect of I-deprenylin rats with carcinogen-induced Mammary tumors. J. Neuroimmunol. 109: 95-104, 2000.	/
	6	Thomas, T; et al. L-Deprenyl: nitric oxide productionand dilation of cerebral blood vessels. NeuroReport, 9:1-6, 1998	/
	7	Thomas, T. Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease. Neurobiol. Aging. 21:343-348, 2000.	√
	8	Thomas T,et al. Aspirin and diabetes: inhibition of amylin aggregation by nonsteroidal Antiinflammatory drugs. Exp Clin Endocrinol Diabetes. 111: 8-11, 2003.	/
	9	Thomas, T. et al. Inhibition of LDL oxidation by the neuroprotective drug 1-deprenyl. Neurol. Res. 24:169-173, 2002	/
	10	Wallace JL and Soldato DL. The therapeutic potential of NO-NSAIDS. Fundamental & Clin Pharmacol. 17: 11-20, 2003.	/

			_
Examiner	` '	Data	7
Signature		Date	- 1
Signature		Considered	ı

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete. including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office. U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES CR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.